Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phio PharmaceuticalsPHIO +4.65%28 EV-to-OCF is 0.47 as of Jul. 31, 2026, which is 34% below its 10-year median of 0.71. GuruFocus rates PHIO with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,410 Biotechnology companies, Phio Pharmaceuticals ranks worse than 75.11% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Phio Pharmaceuticals's Enterprise Value is $-5.07 Mil.
Phio Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-10.71 Mil. Therefore, Phio Pharmaceuticals's EV-to-OCF for today is 0.47.
The historical rank and industry rank for Phio Pharmaceuticals's EV-to-OCF or its related term are showing as below:
PHIO'
s EV-to-OCF Range Over the Past 10 Years
Min: -0.79 Med: 0.71 Max: 1.17
Current: 0.47
During the past 13 years, the highest EV-to-OCF of Phio Pharmaceuticals was 1.17. The lowest was -0.79. And the median was 0.71.
PHIO's EV-to-OCF is ranked worse than 75.11% of 1410
companies
in the Biotechnology industry
Industry Median: -3.345
vs PHIO: 0.47
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Phio Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Phio Pharmaceuticals's share price for today is $1.03.
Phio Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.434.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Phio Pharmaceuticals EV-to-OCF Related Terms
Phio Pharmaceuticals EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Phio Pharmaceuticals's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Phio Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phio Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Phio Pharmaceuticals's EV-to-OCF falls into.
Phio Pharmaceuticals's current Enterprise Value is $-5.07 Mil.
Phio Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phio Pharmaceuticals (PHIO) has a EV-to-OCF of 0.47 as of Jul. 31, 2026. This is 34% below median its historical median of 0.71. According to the industry distribution chart, Phio Pharmaceuticals ranks #1059 out of 1410 companies in the Biotechnology industry, placing it in the top 75.1%.
Is Phio Pharmaceuticals' EV-to-OCF too high?
Phio Pharmaceuticals' current EV-to-OCF of 0.47 is 34% below median its 10-year median of 0.71. Based on the distribution chart, Phio Pharmaceuticals ranks #1059 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Phio Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Phio Pharmaceuticals' EV-to-OCF compare to CALC and INTS?
According to the Biotechnology industry distribution chart, Phio Pharmaceuticals ranks #1059 out of 1410 companies for EV-to-OCF. This places Phio Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Phio Pharmaceuticals's current EV-to-OCF is 0.47, which is 34% below median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phio Pharmaceuticals stock overvalued right now?
Phio Pharmaceuticals (PHIO) has a current EV-to-OCF of 0.47. The current EV-to-OCF is 0.47, which is 34% below median its 10-year median of 0.71. Phio Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Phio Pharmaceuticals (PHIO), the current EV-to-OCF is 0.47 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
28GF Score
Get the complete analysis for PHIO
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHIO has been successfully added to your 
